WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > Biocontamination control in pharmaceutical production
November 11, 2022
I'm For Real
Enter your details once to access all our information and resources
PCUT BioPartners is a commercial biotechnology company that is focused on clinical-stage development of drugs for rare diseases where there is high unmet medical need.
whitePaper | November 19, 2022
Compiling a quality regulatory submission is a basic requirement for biopharmaceutical companies. Poor quality documents could lead to rejection of a regulatory application,
whitePaper | September 17, 2021
The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).
whitePaper | June 8, 2022
For nearly two decades, the Future Today Institute has meticulously researched macro forces of change and the emerging trends that result. Our focus: understanding how these forces and trends will shape our futures.
whitePaper | May 27, 2023
The Human Genome Project was a monumental effort over more than a decade to determine the human DNA sequence and analyze genetic variation among individuals. The hope was that, armed with this understanding, phenotypic differences would be explainable by genetic variation, and health benefits could follow.
Cardinal Health is fortunate to sit at the crossroads of the United States (U.S.) healthcare system, engaging with stakeholders from across the industry including healthcare
whitePaper | October 28, 2022
Adoptive cell therapy (ACT), a branch of immunotherapy, offers a promising treatment for chronic viral infections and malignant diseases such as cancer [1]. This innovative approach involves the autologous or allogenic transplant of immune cells into the patient’s body.
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE